Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative diseases, has filed an S-1 resale registration statement with the SEC for common shares from private placements in 2023 and early 2024. The statement is pending effectiveness and will allow the company to become a reporting issuer, subject to SEC regulations. This move will enable the resale of shares by investors from the private placements, though the securities have not yet been approved by regulatory authorities.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
